Clinical impact of sirolimus‐eluting stent in ST‐segment elevation myocardial infarction: A meta‐analysis of randomized clinical trials

Objectives: To evaluate outcome of patients undergoing sirolimus‐eluting stent (SES) as compared to bare‐metal stent (BMS) implantation during primary angioplasty for ST‐segment elevation myocardial infarction (STEMI). Background: The role of SES in primary percutaneous coronary intervention setting is still debated. Methods: We searched Medline, EMBASE, CENTRAL, scientific session abstracts, and relevant Websites for studies in any language, from the inception of each database until October 2008. Only randomized clinical trials with a mean follow‐up period >6 months and sample size >100 patients were included. Primary endpoint for efficacy was target‐vessel revascularization (TVR) and primary endpoint for safety was stent thrombosis. Secondary endpoints were cardiac death and recurrent myocardial infarction (MI). Results: Six trials were included in the meta‐analysis, including 2,381 patients (1,192 randomized to SES and 1,189 to BMS). Up to 12‐month follow‐up, TVR was significantly lower in patients treated with SES as compared to patients treated with BMS (4.53% vs. 12.53%, respectively; odds ratio [OR] 0.33; 95% confidence interval [CI] 0.24–0.46; P < 0.00001). There were no significant differences in the incidence of stent thrombosis (3.02% vs. 3.70%, OR = 0.81 [95% CI, 0.52–1.27], P = 0.81), cardiac death (2.77% vs. 3.28%, OR = 0.84 [95% CI, 0.52–1.35], P = 0.47), and recurrent MI (2.94% vs. 4.04%, OR = 0.71 [95% CI, 0.45–1.11], P = 0.13) between the two groups. Conclusion: SES significantly reduces TVR rates as compared to BMS in STEMI patients up to 1 year follow‐up. Further studies with larger population and longer follow‐up time are needed to confirm our findings. © 2009 Wiley‐Liss, Inc.

[1]  M. Pittler.  Systematic Reviews in Health Care: Meta‐analysis in Context , 2010 .

[2]  B. Brodie,et al.  Outcomes with drug‐eluting stents versus bare metal stents in acute ST‐elevation myocardial infarction: Results from the Strategic Transcatheter Evaluation of New Therapies (STENT) Group , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[3]  M. Zwahlen,et al.  Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. , 2008, Journal of the American College of Cardiology.

[4]  S. Normand,et al.  Drug-eluting or bare-metal stents for acute myocardial infarction. , 2008, The New England journal of medicine.

[5]  Deepak L. Bhatt,et al.  Long-term impact of drug-eluting stents versus bare-metal stents on all-cause mortality. , 2008, Journal of the American College of Cardiology.

[6]  Aloke V. Finn,et al.  Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients: An Autopsy Study , 2008, Circulation.

[7]  P. Serruys,et al.  Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Long-Term Outcome After Bare Metal and Drug-Eluting Stent Implantation , 2008, Circulation. Cardiovascular interventions.

[8]  G. Stone,et al.  Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. , 2008, International journal of cardiology.

[9]  F. Prati,et al.  Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. , 2008, JAMA.

[10]  C. Terkelsen,et al.  Randomized comparison of distal protection versus conventional treatment in primary percutaneous coronary intervention: the drug elution and distal protection in ST-elevation myocardial infarction (DEDICATION) trial. , 2008, Journal of the American College of Cardiology.

[11]  H. Putter,et al.  Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. , 2008, Journal of the American College of Cardiology.

[12]  K. Furie,et al.  Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2008, Circulation.

[13]  John Bresnahan,et al.  Outcomes of Stent Thrombosis and Restenosis During Extended Follow-Up of Patients Treated With Bare-Metal Coronary Stents , 2007, Circulation.

[14]  P. Grayburn,et al.  Safety of drug-eluting stents in the coronary artery in ST-elevation myocardial infarction at a single high-volume medical center. , 2007, The American journal of cardiology.

[15]  G. Biondi Zoccai,et al.  Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (SELECTION). , 2007, Journal of interventional cardiology.

[16]  R. Jaffe,et al.  Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives. , 2007, Journal of the American College of Cardiology.

[17]  R. Ferrari,et al.  Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study. , 2007, Journal of the American College of Cardiology.

[18]  Ángel Martínez,et al.  Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. , 2007, American heart journal.

[19]  Arianna Azzellino,et al.  Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). , 2007, Journal of the American College of Cardiology.

[20]  K. Eagle,et al.  Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. , 2007, JAMA.

[21]  P. Serruys,et al.  Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). , 2007, The American journal of cardiology.

[22]  J. Ottervanger,et al.  External validity of ST elevation myocardial infarction trials: The Zwolle studies , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[23]  Johan Lindbäck,et al.  Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. , 2007, The New England journal of medicine.

[24]  Patrick Hunziker,et al.  Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. , 2006, Journal of the American College of Cardiology.

[25]  E. Bramucci,et al.  Sirolimus-eluting versus uncoated stents in acute myocardial infarction. , 2006, The New England journal of medicine.

[26]  J. Tijssen,et al.  Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. , 2006, The New England journal of medicine.

[27]  Deepak L. Bhatt,et al.  Bare metal stent restenosis is not a benign clinical entity. , 2006, American heart journal.

[28]  Barbara T. Unger,et al.  Comparison of safety and efficacy of sirolimus-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction. , 2006, The American journal of cardiology.

[29]  Fesc,et al.  Safety of Coronary Sirolimus-Eluting Stents in Daily Clinical Practice: One-Year Follow-Up of the e-Cypher Registry , 2006, Circulation.

[30]  V. Gama-Ribeiro,et al.  Long-term results (three to five years) of the Restenosis Intrastent: Balloon angioplasty versus elective Stenting (RIBS) randomized study. , 2005, Journal of the American College of Cardiology.

[31]  S. Yusuf,et al.  Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. , 2005, JAMA.

[32]  F. Burzotta,et al.  Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: a metaregression. , 2005, American heart journal.

[33]  M. Johnston,et al.  Evaluating the role of quality assessment of primary studies in systematic reviews of cancer practice guidelines , 2005, BMC medical research methodology.

[34]  Thomas McGinn,et al.  Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic) , 2004, Canadian Medical Association Journal.

[35]  K. Kent,et al.  Usefulness of periprocedural creatinine phosphokinase-MB release to predict adverse outcomes after intracoronary radiation therapy for in-stent restenosis. , 2004, The American journal of cardiology.

[36]  Jörg Hausleiter,et al.  Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. , 2004, American heart journal.

[37]  William Wijns,et al.  Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS) , 2003, The Lancet.

[38]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[39]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[40]  J. Brophy,et al.  Evidence for Use of Coronary Stents: A Hierarchical Bayesian Meta-Analysis , 2003, Annals of Internal Medicine.

[41]  J. Boura,et al.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction : a quantitative review of 23 randomised trials , 2022 .

[42]  Richard R. Heuser,et al.  Randomized Trial of 90Sr/90Y β-Radiation Versus Placebo Control for Treatment of In-Stent Restenosis , 2002 .

[43]  P. Teirstein,et al.  Randomized Trial of 90Sr/90Y &bgr;-Radiation Versus Placebo Control for Treatment of In-Stent Restenosis , 2002, Circulation.

[44]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[45]  George Davey Smith,et al.  Where now for meta-analysis? , 2002, International journal of epidemiology.

[46]  Ousa,et al.  A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .

[47]  J. Sterne,et al.  Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. , 2000, Journal of clinical epidemiology.

[48]  I. Olkin,et al.  Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement , 1999, The Lancet.

[49]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[50]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[51]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[52]  K. Dickersin,et al.  Meta-analysis: state-of-the-science. , 1992, Epidemiologic reviews.

[53]  W. Willett,et al.  Misinterpretation and misuse of the kappa statistic. , 1987, American journal of epidemiology.

[54]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[55]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.